Use our chat feature to speak with one of our expert consultants who can help you identify if medical cannabis can help you.
4 min read
Emily Ledger
One month ago, we announced our first-of-its-kind partnership with Glass Pharms® - an arrangement that aims to reduce hurdles between the prescription and receipt of medical cannabis products in the UK. One month on, we have been thrilled to see how this partnership has brought medical cannabis into the mainstream news once again.
With that in mind, here’s a quick round-up of all the press coverage of the Releaf x Glass Pharms partnership, and why such coverage remains as important as ever for the medical cannabis sector.
On the 10th of June, we announced our supply partnership with Glass Pharms® Ltd - an arrangement that, for the first time, has seen UK patients receive high-quality UK-grown medical cannabis products.
Having struggled to keep up with patients’ needs due to an unpredictable and unreliable international supply chain, we share Glass Pharms’ mission to improve patient access to the medical cannabis products that work for them.
This unique partnership allowed us to be the first clinic in the UK to offer patients medical cannabis cultivars that were 'Made in Britain'. With significant research and development, Glass Pharms has created a range of products that are suitable for treating a wide range of symptoms, which are now available with Releaf’s plastic-free branded packaging.
Several news sources covered our partnership with Glass Pharms, highlighting the story of one of our patients, Chloe Durrington, who became the first patient to receive prescribed medical cannabis flower that was grown here in the UK.
As Glass Pharms’ Chief Executive, James Duckenfield, explained in The Sunday Times, Chloe, who has a medical cannabis prescription to treat Endometriosis, is the first of many patients who “will now have a security of supply that was previously missing from a market that relied on imports…
“Our continuous harvesting model will help bring an end to the out-of-stock issues that have set back the development of this promising therapeutic area.”
Chloe also explained, as reported by Farming Online, how access to UK-grown medical cannabis products will give her peace of mind moving forward with her treatment:
“From an environmental point-of-view, it feels good to know that my medication hasn’t had to travel across the globe to get to me.
“Plus, it gives me peace of mind that issues with supply, which have until now been one of the main challenges for patients like me, are far less likely if the cannabis isn’t coming from overseas.”
The new partnership was also reported by Yahoo! Finance and Business of Cannabis, who all noted Glass Pharms’ innovative and environment-focused approach to medical cannabis cultivation.
Glass Pharms’ employs AI-controlled growing conditions and laboratory facilities which take plants through a 12-week grow journey. Their state-of-the-art facilities ensure batch-to-batch consistency and adherence to the highest quality standards set by the MHRA and Home Office. Their innovative approach to cannabis cultivation also uses around 40% of the power utilised by conventional indoor growing methods has helped Glass Pharms to achieve a carbon-negative operation.
While medical cannabis was legalised in the UK in 2018, there remains significant stigma around the industry. This, coupled with the ongoing difficulties around promoting medical cannabis in the mainstream media, can make it extremely difficult to raise awareness and highlight the often life-changing benefits of medical cannabis.
Coverage from media outlets such as those noted in this article is crucial in an industry that remains overshadowed by stigma and prejudice. We hope that continued exposure to these stories will help to raise awareness for patients like Chloe, for whom reliable access to medical cannabis is essential.
Rupa Shah, Releaf's Compliance Director and former ASA Investigations Executive, comments:
“Navigating the stringent advertising regulations surrounding cannabis in the UK presents a significant challenge for medical cannabis clinics, despite the legalisation of medical cannabis in 2018.
“Our landmark partnership with Glass Pharms signifies a crucial step forward for Releaf, allowing us to openly discuss the industry and the benefits of medical cannabis with integrity and compliance.
“This first-of-its-kind collaboration underscores our commitment to advancing the medical cannabis industry within legal and ethical boundaries.”
At Releaf, we are excited to continue our partnership with Glass Pharms to provide high-quality, UK-grown medical cannabis products to our patients. We hope the coverage of this partnership will continue to raise awareness around the important work being done in the medical cannabis industry to improve patient access to the life-changing medicines that work for them. Continued reporting on the latest news on medical cannabis will hopefully help to further diminish the stigma around this treatment and its patients.
It is important to seek medical advice before starting any new treatments. The patient advisors at Releaf are available to provide expert advice and support. Alternatively, click here to book a consultation with one of our specialist doctors.
Get comprehensive care, convenience, and confidence with an all-in-one treatment plan.
Am I eligible?Emily, an accomplished content writer with a specialisation in cannabis and alternative health, leverages her five years in the sector to enhance education and diminish stigma around medicinal cannabis use.
All of our articles are written by medical cannabis experts, guided by strict sourcing guidelines, and reference peer-reviewed studies and credible academic research. Our expert clinical team and compliance specialists provide valuable insights to ensure accuracy when required. Learn more in our editorial policy.
Need more help?
Unfortunately, not many actually know what a pancreas does, until it starts causing them health concerns that is, and what makes this even more worrying is that pancreatic cancer is the 10th most common cancer in the UK.
Lucy MacKinnon
November is National COPD Awareness Month, a time dedicated to raising awareness of Chronic Obstructive Pulmonary Disease (COPD) and the prevention and treatment of chronic lung disease. In honour of this important event, we’re taking a closer look at the relationship between medical cannabis and chronic lung disease and answering the question: “Can I vape medical cannabis if I have COPD?”
Emily Ledger
Medical cannabis treatment is quite an individual process, which means there is no one-size-fits-all answer to the question of how often you should see your doctor. Each and every patient we see here at Releaf responds at least slightly differently to their treatment protocol. This is the main reason our world-class clinical team takes such a personalised approach to each patient's care and why it is essential that all patients see their doctor regularly.
Sam North
